Optiscan Imaging Ltd
ASX:OIL
Optiscan Imaging Ltd
EPS (Diluted)
Optiscan Imaging Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
EPS (Diluted)
AU$5
|
CAGR 3-Years
13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Optiscan Imaging Ltd
Glance View
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The company is headquartered in Mulgrave, Victoria. The firm has developed and commercialized confocal microscopes for clinical and pre-clinical applications. Its endomicroscopic technology enables 3D, in-vivo imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery. Its InVivage device is developed for clinical use in the oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a miniaturised confocal endomicroscope used for cellular level in-vivo imaging in living tissues. The firm also provides customization options for its product, (FIVE2).
See Also
What is Optiscan Imaging Ltd's EPS (Diluted)?
EPS (Diluted)
-0
AUD
Based on the financial report for Dec 31, 2024, Optiscan Imaging Ltd's EPS (Diluted) amounts to -0 AUD.
What is Optiscan Imaging Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
0%
Over the last year, the EPS (Diluted) growth was 0%.
You don't have any saved screeners yet